Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Brain-Avoidant Proton Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases from Solid Tumor Malignancies, BRAVO-LM Trial

Trial Status: active

This clinical trial studies the side effects and how well brain-avoidant (BRAVO) proton craniospinal irradiation (pCSI) works in treating patients with solid tumor malignancies that have spread from where they first started (primary site) to the spinal fluid around the brain and spinal cord (leptomeninges metastases [LM]). One of the most effective treatments for LM is pCSI which treats the entire brain and spinal cord with radiation. However, pCSI causes long-term changes in the brain and reduces the ability to learn and remember new things. BRAVO pCSI is a modified pCSI approach which avoids treating the parts of the brain that are most important for learning and memory, including an area called the hippocampus. BRAVO pCIS may be an effective way to treat LM from solid tumor malignancies and may also protect learning and memory.